NDUBUISI CHRISTOPHER EDEOGA MD
Prescription History 1497919039
Internal Medicine - Infectious Disease in Port Charlotte, FL


Quality Rating: 75 out of 100 score

NPI Status: Active since July 14, 2008

Contact Information

21205 OLEAN BLVD
STE A
PORT CHARLOTTE, FL
ZIP 33952
Phone: (941) 613-2800
Fax: (941) 613-2801

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for NDUBUISI CHRISTOPHER EDEOGA MD, an active Infectious Disease specialist practicing in Port Charlotte, FL. Our medical registry currently tracks 10 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 599 documented patient claims. Among these therapy options, the most frequently utilized medication is Vancomycin Hcl, which accounts for 144 claims alone.


Biktarvy

Generic Formulation: Bictegrav/Emtricit/Tenofov AlaSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 23
30-Day Fills 23.0
Days Supply 690
FL State Average Benchmarks
Peer Average Claims98.0
Peer Average 30-Day Fills100.6
Peer Average Days Supply3,011
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 76.5% less volume than the regional standard for practitioners inside FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $92,751.29 across this reporting matrix range.

Provider Avg Cost Per Claim

$4,032.66

State Avg Cost Per Claim

$3,874.87

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This combination product is used by itself to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. This product is a combination of 3 different drugs: bictegravir, emtricitabine, and tenofovir alafenamide. Bictegravir is called an integrase strand transfer inhibitor-INSTI. Emtricitabine is called a nucleoside reverse transcriptase inhibitor, while tenofovir alafenamide is called a nucleotide reverse transcriptase inhibitor. Emtricitabine and tenofovir alafenamide are often called NRTIs. Bictegravir/emtricitabine/tenofovir alafenamide is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Cefazolin Sodium

Generic Formulation: Cefazolin SodiumSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 35
30-Day Fills 35.0
Days Supply 246
FL State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills20.2
Peer Average Days Supply130
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 75.0% higher than the standard regional baseline profile for FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,239.72 across this reporting matrix range.

Provider Avg Cost Per Claim

$63.99

State Avg Cost Per Claim

$67.07

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.

Therapeutic Applications

Cefazolin is an antibiotic used to treat a wide variety of bacterial infections. It may also be used before and during certain surgeries to help prevent infection. This medication is known as a cephalosporin antibiotic. It works by stopping the growth of bacteria.

Cefdinir

Generic Formulation: CefdinirSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 45
30-Day Fills 54.9
Days Supply 1,145
FL State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills29.6
Peer Average Days Supply245
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 55.2% higher than the standard regional baseline profile for FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,999.24 across this reporting matrix range.

Provider Avg Cost Per Claim

$44.43

State Avg Cost Per Claim

$21.46

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A third-generation oral cephalosporin antibacterial agent that is used to treat bacterial infections of the respiratory tract and skin.

Therapeutic Applications

Cefdinir is used to treat a wide variety of bacterial infections. This medication is known as a cephalosporin antibiotic. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Cefepime Hcl

Generic Formulation: Cefepime HclSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 104
30-Day Fills 104.0
Days Supply 691
FL State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills28.7
Peer Average Days Supply179
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 271.4% higher than the standard regional baseline profile for FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $26,788.45 across this reporting matrix range.

Provider Avg Cost Per Claim

$257.58

State Avg Cost Per Claim

$245.21

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A fourth-generation cephalosporin antibacterial agent that is used in the treatment of infections, including those of the abdomen, urinary tract, respiratory tract, and skin. It is effective against PSEUDOMONAS AERUGINOSA and may also be used in the empiric treatment of FEBRILE NEUTROPENIA.

Therapeutic Applications

Cefepime is used to treat a wide variety of bacterial infections. This medication belongs to a class of drugs known as cephalosporin antibiotics. It works by stopping the growth of bacteria.

Ceftriaxone

Generic Formulation: Ceftriaxone SodiumSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 121
30-Day Fills 121.0
Days Supply 800
FL State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills28.8
Peer Average Days Supply156
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 332.1% higher than the standard regional baseline profile for FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $13,946.03 across this reporting matrix range.

Provider Avg Cost Per Claim

$115.26

State Avg Cost Per Claim

$82.45

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A broad-spectrum cephalosporin antibiotic and cefotaxime derivative with a very long half-life and high penetrability to meninges, eyes and inner ears.

Therapeutic Applications

Ceftriaxone is used to treat a wide variety of bacterial infections. This medication belongs to a class of drugs known as cephalosporin antibiotics. It works by stopping the growth of bacteria. This drug is not recommended for use in newborns with high blood bilirubin levels and premature infants due to increased risk of side effects. Ask the doctor or pharmacist for details.

Daptomycin

Generic Formulation: DaptomycinSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 19
30-Day Fills 19.0
Days Supply 117
FL State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills30.2
Peer Average Days Supply195
Conservative Utilization

This provider writes prescriptions for this formulation 36.7% less frequently than the standard regional baseline metric for practitioners inside FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $16,411.66 across this reporting matrix range.

Provider Avg Cost Per Claim

$863.77

State Avg Cost Per Claim

$1,343.94

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cyclic lipopeptide antibiotic that inhibits GRAM-POSITIVE BACTERIA.

Therapeutic Applications

This medication is an antibiotic used to treat serious bacterial infections. It works by stopping the growth of bacteria. This medication is not recommended for use in children younger than 12 months due to possible risk of serious side effects.

Doxycycline Hyclate

Generic Formulation: Doxycycline HyclateSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 68
30-Day Fills 98.9
Days Supply 2,587
FL State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills36.7
Peer Average Days Supply492
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 100.0% higher than the standard regional baseline profile for FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,496.80 across this reporting matrix range.

Provider Avg Cost Per Claim

$51.42

State Avg Cost Per Claim

$24.49

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic tetracycline derivative with similar antimicrobial activity.

Therapeutic Applications

This medication is used to treat a wide variety of bacterial infections, including those that cause acne. This medication is also used to prevent malaria. This medication is known as a tetracycline antibiotic. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Ertapenem

Generic Formulation: Ertapenem SodiumSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 28
30-Day Fills 28.0
Days Supply 192
FL State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills25.1
Peer Average Days Supply146
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $22,096.88 across this reporting matrix range.

Provider Avg Cost Per Claim

$789.17

State Avg Cost Per Claim

$567.68

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A carbapenem derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of Gram-positive and Gram-negative bacterial infections including intra-abdominal infections, acute gynecological infections, complicated urinary tract infections, skin infections, and respiratory tract infections. It is also used to prevent infection in colorectal surgery.

Therapeutic Applications

Ertapenem is used to prevent and treat a wide variety of bacterial infections. This medication is known as a carbapenem-type antibiotic. It works by stopping the growth of bacteria.

Metronidazole

Generic Formulation: MetronidazoleSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 177
FL State Average Benchmarks
Peer Average Claims11.0
Peer Average 30-Day Fills11.0
Peer Average Days Supply38
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $199.91 across this reporting matrix range.

Provider Avg Cost Per Claim

$16.66

State Avg Cost Per Claim

$16.50

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.

Therapeutic Applications

This medication is used on the skin to treat a certain skin disorder known as rosacea, a type of adult acne. It may help to decrease redness, swelling and the number of pimples caused by rosacea. This medication is an antibiotic. For the treatment of rosacea, metronidazole is believed to work by decreasing swelling (inflammation). Some brands of this medication also contain sunscreens (see also Notes section).

Vancomycin Hcl

Generic Formulation: Vancomycin HclSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 144
30-Day Fills 144.0
Days Supply 997
FL State Average Benchmarks
Peer Average Claims16.0
Peer Average 30-Day Fills17.0
Peer Average Days Supply45
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 800.0% higher than the standard regional baseline profile for FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $22,834.50 across this reporting matrix range.

Provider Avg Cost Per Claim

$158.57

State Avg Cost Per Claim

$77.81

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.

Therapeutic Applications

Vancomycin is an antibiotic used to treat infections. This form of vancomycin is used to treat a certain intestinal condition (colitis) caused by bacteria. This condition causes diarrhea and stomach/abdominal discomfort or pain. When vancomycin is taken by mouth, it stays in the intestines to stop the growth of certain bacteria that cause these symptoms. This antibiotic treats only bacterial infection in the intestines. It will not work for bacterial infections in any other part of the body or for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like NDUBUISI CHRISTOPHER EDEOGA MD provides transparency into local medical care patterns within Port Charlotte, FL.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Infectious Disease** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.